Henrik Vestergaard

Henrik Vestergaard

Auto-generated profile, based on publicly available information

Henrik Vestergaard

Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2015 in Nature
Verified
Journal Article
Open access
PDF file
SFSofia Kirke Forslund
Sofia Kirke Forslund
FHFalk Hildebrand
Falk Hildebrand
TNTrine Nielsen
Trine Nielsen
GFGwen Falony
Gwen Falony
ECEmmanuelle Le Chatelier
Emmanuelle Le Chatelier
OPOluf Pedersen
Oluf Pedersen
Growing evidence from metagenome-wide association studies link multiple common disorders to microbial dysbiosis but effects of drug treatment are often not accounted for; here, the authors re-analyse two previous metagenomic studies of type 2 diabetes mellitus patients together with a novel cohort to determine the effects of the widely prescribed antidiabetic drug metformin and highlight the need to distinguish the effects of a disease from the effects of treatment on the gut microbiota. There is growing evidence from metagenome-wide association studies that several common human disorders, such as type 2 diabetes mellitus (T2D), are associated with intestinal dysbiosis, an unhealthy imbalance of the gut microbiota. However, the contribution of antidiabetic drug treatment to dysbiosis is often not accounted for. Oluf Pedersen and colleagues analysed two previous metagenomic studies of T2D patients that yielded divergent conclusions regarding the association of the disease with dysbiosis, together with a novel cohort, to determine the effects of the widely prescribed antidiabetic drug metformin. They find that metformin is indeed a confounding factor, but that a unified signature of gut microbiome shifts in T2D is still apparent. In recent years, several associations between common chronic human disorders and altered gut microbiome composition and function have been reported1,2. In most of these reports, treatment regimens were not controlled for and conclusions could thus be confounded by the effects of various drugs on the microbiota, which may obscure microbial causes, protective factors or diagnostically relevant signals. Our study addresses disease and drug signatures in the human gut microbiome of type 2 diabetes mellitus (T2D). Two previous quantitative gut metagenomics studies of T2D patients that were unstratified for treatment yielded divergent conclusions regarding its associated gut microbial dysbiosis3,4. Here we show, using 784 available human gut metagenomes, how antidiabetic medication confounds these results, and analyse in detail the effects of the most widely used antidiabetic drug metformin. We provide support for microbial mediation of the therapeutic effects of metformin through short-chain fatty acid production, as well as for potential microbiota-mediated mechanisms behind known intestinal adverse effects in the form of a relative increase in abundance of Escherichia species. Controlling for metformin treatment, we report a unified signature of gut microbiome shifts in T2D with a depletion of butyrate-producing taxa3,4. These in turn cause functional microbiome shifts, in part alleviated by metformin-induced changes. Overall, the present study emphasizes the need to disentangle gut microbiota signatures of specific human diseases from those of medication.

9 December 2021 in Nature
Verified
Journal Article
Closed access
PDF file
SGSarah E. Graham
Sarah E. Graham
SCShoa L. Clarke
Shoa L. Clarke
KWKuan-Han H. Wu
Kuan-Han H. Wu
Stavroula KanoniStavroula Kanoni
Stavroula Kanoni
GZGreg J. M. Zajac
Greg J. M. Zajac
CWCristen J. Willer
Cristen J. Willer

1 February 2017 in Nature
Verified
Journal Article
Open access
PDF file
EMEirini Marouli
Eirini Marouli
MGMariaelisa Graff
Mariaelisa Graff
CGCarolina Medina Gomez
Carolina Medina Gomez
KLKen Sin Lo
Ken Sin Lo
AWAndrew R. Wood
Andrew R. Wood
GLGuillaume Lettre
Guillaume Lettre
Height is a highly heritable, classic polygenic trait with approximately 700 common associated variants identified through genome-wide association studies so far. Here, we report 83 height-associated coding variants with lower minor-allele frequencies (in the range of 0.1–4.8%) and effects of up to 2 centimetres per allele (such as those in IHH, STC2, AR and CRISPLD2), greater than ten times the average effect of common variants. In functional follow-up studies, rare height-increasing alleles of STC2 (giving an increase of 1–2 centimetres per allele) compromised proteolytic inhibition of PAPP-A and increased cleavage of IGFBP-4 in vitro, resulting in higher bioavailability of insulin-like growth factors. These 83 height-associated variants overlap genes that are mutated in monogenic growth disorders and highlight new biological candidates (such as ADAMTS3, IL11RA and NOX4) and pathways (such as proteoglycan and glycosaminoglycan synthesis) involved in growth. Our results demonstrate that sufficiently large sample sizes can uncover rare and low-frequency variants of moderate-to-large effect associated with polygenic human phenotypes, and that these variants implicate relevant genes and pathways.

12 July 2004 in Archives of internal medicine (1960)
Verified
Journal Article
Closed access
PDF file
TAThomas Almdal
Thomas Almdal
HSHenrik Scharling
Henrik Scharling
JJJan Skov Jensen
Jan Skov Jensen
HVHenrik Vestergaard
Henrik Vestergaard
Research from JAMA Internal Medicine — The Independent Effect of Type 2 Diabetes Mellitus on Ischemic Heart Disease, Stroke, and Death — A Population-Based Study of 13 000 Men and Women With 20 Years of Follow-up

6 May 2020 in Nature
Verified
Journal Article
Closed access
PDF file
SVSara Vieira-Silva
Sara Vieira-Silva
GFGwen Falony
Gwen Falony
EBEugeni Belda
Eugeni Belda
TNTrine Nielsen
Trine Nielsen
JAJudith Aron-Wisnewsky
Judith Aron-Wisnewsky
JRJeroen Raes
Jeroen Raes

27 June 2016 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
HRHenrik Munch Roager
Henrik Munch Roager
LHLea B. S. Hansen
Lea B. S. Hansen
MBMartin I. Bahl
Martin I. Bahl
HFHenrik L. Frandsen
Henrik L. Frandsen
VCVera Carvalho
Vera Carvalho
TLTine R. Licht
Tine R. Licht